{
  "docId": "019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "docSlug": "6f650cb16e144ff2cbcc39c10e5d03e1",
  "documentTitle": "23andMe | Investor Presentation Deck | 39 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 39,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a process flow to demonstrate the predictive power of their genomic platform.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8cfe-74f8-8267-71bfaaa75a6b/14",
  "deckHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b",
  "deckJsonHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b.json",
  "deckAnchorHref": "/decks/019de076-8cfe-74f8-8267-71bfaaa75a6b#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.26,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Bar chart showing % of Phase 1 participants experiencing specific adverse events at different dose levels.",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "124c5831-5a29-4aff-bd51-351666a3c7d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.24,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Stacked bar charts for CD200R1 and DOK2 showing associations with cancer and immune conditions.",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d934cab-7570-43a6-8ab5-a81850862e35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Heatmap showing signed log(p) values for CTLA4 gene variants across various diseases.",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7063f66-2d2c-4274-a68c-26b31fa1d714",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.72,
        "x": 0.14,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "23andMe 'IO Signature' -> 23ME-00610 Lead Asset -> Genomic data successfully predicted '610 AE Profile",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b58a4ab2-f2e8-4f2c-aae7-b498741eb05a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.26,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "paragraph",
      "text": "*Currently in Phase 2a portion of Phase 1/2a",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84ea801b-a999-479b-b8a2-93b9da216dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.72,
        "x": 0.14,
        "y": 0.05
      },
      "kind": "title",
      "text": "NEED: Our Unique Approach to De-risk Development: Leveraging Pleiotropy to Characterize Novel Cancer Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3409fb12-d447-4a61-8d66-bc6b03bf6ebc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "d272da66-5366-4a5d-a300-b375e87eba00",
      "evidence": "bar chart showing % of Phase 1 participants experiencing specific adverse events at different dose levels",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "e2f1d349-2e34-4978-9b9c-b4bf12ff4592",
      "evidence": "The slide maps a logical progression from genomic signature to asset development to clinical outcome prediction.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 39,
      "from": 9,
      "beatId": "93eec936-fceb-4bb2-ab9b-6265df978407",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-39 present 23andMe's solution, including their therapeutic pipeline and approach",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}